eton
pharmaceuticals
prices
underwritten
public
offering
common
stock
deer
park
globe
newswire
eton
pharmaceuticals
inc
nasdaq
eton
specialty
pharmaceutical
company
focused
developing
commercializing
innovative
treatments
rare
pediatric
diseases
today
announced
pricing
underwritten
public
offering
shares
common
stock
price
public
per
share
gross
proceeds
million
company
also
granted
underwriters
option
purchase
price
per
share
underwriters
paid
initial
shares
additional
shares
cover
connection
offering
exercised
full
would
increase
gross
proceeds
million
offering
expected
close
october
subject
customary
closing
conditions
eton
pharmaceuticals
intends
use
net
proceeds
offering
primarily
general
corporate
purposes
may
include
research
development
activities
capital
expenditures
selling
general
administrative
costs
meet
working
capital
needs
national
securities
corporation
wholly
owned
subsidiary
national
holdings
nasdaq
nhld
acting
sole
manager
offering
liquid
venture
partners
group
national
securities
responsible
sourcing
executing
offering
shares
described
offered
eton
pharmaceuticals
pursuant
registration
statement
previously
filed
subsequently
declared
effective
securities
exchange
commission
sec
preliminary
prospectus
supplement
relating
offering
filed
sec
final
prospectus
supplement
filed
sec
final
prospectus
supplement
available
sec
website
http
press
release
shall
constitute
offer
sell
solicitation
offer
buy
securities
described
herein
shall
sale
securities
state
jurisdiction
offer
solicitation
sale
would
unlawful
prior
registration
qualification
securities
laws
state
jurisdiction
copy
final
prospectus
supplement
relating
offering
may
obtained
available
national
securities
corporation
attn
charles
wanyama
ecm
vesey
street
floor
new
york
ny
email
cwanyama
telephone
eton
pharmaceuticals
eton
pharmaceuticals
specialty
pharmaceutical
company
focused
developing
commercializing
innovative
treatments
rare
pediatric
diseases
company
currently
owns
receives
royalties
three
approved
products
including
sprinkle
alaway
preservative
six
additional
products
pipeline
including
five
submitted
fda
safe
harbor
press
release
contains
statements
regarding
expected
closing
public
offering
intended
use
proceeds
offering
offering
subject
customary
closing
conditions
assurance
whether
offering
completed
statements
involve
known
unknown
risks
uncertainties
factors
could
cause
actual
results
differ
materially
including
risks
disclosed
section
risk
factors
included
preliminary
prospectus
supplement
filed
sec
october
eton
pharmaceuticals
cautions
readers
place
undue
reliance
statements
company
undertake
specifically
disclaims
obligation
update
revise
statements
reflect
new
circumstances
unanticipated
events
occur
company
contact
david
krempa
dkrempa
